Addex Therapeutics (ADR) (ADXN)
Develops allosteric CNS drug candidates through internal programs, partnerships, and investments.
Something off on this page? Send us feedback.
Develops oral small-molecule allosteric modulators for neurological disorders, including dipraglurant, ADX71149 and GABAB programs for chronic cough and substance use disorders. Commercialization is limited to licensing selected programs, while partner-led development and a minority Neurosterix stake extend the pipeline beyond a three-person internal operation.
Develops oral small-molecule allosteric modulators for central nervous system disorders from Geneva. The internal portfolio centers on dipraglurant, an mGlu5 negative allosteric modulator being evaluated for brain-injury recovery; ADX71149, a returned clinical-stage mGlu2 positive allosteric modulator; and a preclinical GABAB positive allosteric modulator for chronic cough.
Extends the platform through external relationships: Indivior advances a licensed GABAB program for substance-use disorders, while a minority Neurosterix interest provides exposure to M4 and mGlu7 programs. An investment in Stalicla adds exposure to precision neuropsychiatry.
Operates as a three-person, single-segment clinical-stage developer. Commercialization is limited to licensing, and portfolio advancement depends on clinical testing, regulatory approval, partner execution, and new collaborative or financing arrangements.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $1.2M · Total debt $126.3K · Total assets $5.9M · Shareholders' equity $4.1M
- Revenue
- $9.5K
- Operating income
- −$592.8K
- Net income
- −$2.1M
Reported in CHF, converted at the latest exchange rate
No dividends on record.
| Insiders7 holders · as of Mar 25, 2026 | 60.22% | 741.8K ADS | |
| Otherremainder | 39.78% | 490.1K ADS |
1.23M ADS (1 ADS = 30 ordinary shares) as of Aug 22, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
The reported float (578.7K, 80.3% free) does not reconcile with the share count, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Timothy Mark DyerInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 45.59% | 16.85M ordinary | Form 4filed Mar 18, 2026 ↗ |
Vincent Michael LawtonInsiderdirector | 6.79% | 2.51M ordinary | Form 4filed Mar 25, 2026 ↗ |
Raymond George HillInsiderdirector | 3.69% | 1.37M ordinary | Form 4filed Mar 25, 2026 ↗ |
Roger MillsInsiderdirector, officer: CHIEF MEDICAL OFFICER | 2.13% | 785,976 ordinary | Form 4filed Mar 25, 2026 ↗ |
Mikhail KalinichevInsiderofficer: HEAD OF TRANSLATIONAL SCIENCE | 0.83% | 306,765 ordinary | Form 4filed Mar 25, 2026 ↗ |
| See all 15 → | |||
Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
Not reported.